Phathom Pharmaceuticals I... (PHAT)
Phathom Pharmaceuticals Statistics
Share Statistics
Phathom Pharmaceuticals has 68.38M shares outstanding. The number of shares has increased by 16.93% in one year.
| Shares Outstanding | 68.38M |
| Shares Change (YoY) | 16.93% |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 38.09M |
| Failed to Deliver (FTD) Shares | 547 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 14.2M, so 20.77% of the outstanding shares have been sold short.
| Short Interest | 14.2M |
| Short % of Shares Out | 20.77% |
| Short % of Float | 40.7% |
| Short Ratio (days to cover) | 14.61 |
Valuation Ratios
The PE ratio is -2.32 and the forward PE ratio is -1.75. Phathom Pharmaceuticals's PEG ratio is 0.07.
| PE Ratio | -2.32 |
| Forward PE | -1.75 |
| PS Ratio | 686.61 |
| Forward PS | 0.5 |
| PB Ratio | -6.44 |
| P/FCF Ratio | -3.36 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Phathom Pharmaceuticals Inc. has an Enterprise Value (EV) of 225.91M.
| EV / Earnings | -1.12 |
| EV / Sales | 331.24 |
| EV / EBITDA | -1.42 |
| EV / EBIT | -1.35 |
| EV / FCF | -1.62 |
Financial Position
The company has a current ratio of 10.25, with a Debt / Equity ratio of -1.91.
| Current Ratio | 10.25 |
| Quick Ratio | 10.22 |
| Debt / Equity | -1.91 |
| Total Debt / Capitalization | 209.79 |
| Cash Flow / Debt | -0.99 |
| Interest Coverage | -3.99 |
Financial Efficiency
Return on equity (ROE) is 2.77% and return on capital (ROIC) is -252.47%.
| Return on Equity (ROE) | 2.77% |
| Return on Assets (ROA) | -0.49% |
| Return on Capital (ROIC) | -252.47% |
| Revenue Per Employee | $1,508.85 |
| Profits Per Employee | $-446,000 |
| Employee Count | 452 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.14 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -49.37% in the last 52 weeks. The beta is 0.64, so Phathom Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -49.37% |
| 50-Day Moving Average | 6.6 |
| 200-Day Moving Average | 11.39 |
| Relative Strength Index (RSI) | 36.22 |
| Average Volume (20 Days) | 998.34K |
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of 682K and earned -201.59M in profits. Earnings per share was -3.93.
| Revenue | 682K |
| Gross Profit | 515K |
| Operating Income | -167.31M |
| Net Income | -201.59M |
| EBITDA | -159.05M |
| EBIT | -167.31M |
| Earnings Per Share (EPS) | -3.93 |
Balance Sheet
The company has 381.39M in cash and 139.03M in debt, giving a net cash position of 242.36M.
| Cash & Cash Equivalents | 381.39M |
| Total Debt | 139.03M |
| Net Cash | 242.36M |
| Retained Earnings | -928.68M |
| Total Assets | 387.04M |
| Working Capital | 308.53M |
Cash Flow
In the last 12 months, operating cash flow was -137.58M and capital expenditures -1.63M, giving a free cash flow of -139.21M.
| Operating Cash Flow | -137.58M |
| Capital Expenditures | -1.63M |
| Free Cash Flow | -139.21M |
| FCF Per Share | -2.71 |
Margins
Gross margin is 75.51%, with operating and profit margins of -24.53K% and -29.56K%.
| Gross Margin | 75.51% |
| Operating Margin | -24.53K% |
| Pretax Margin | -29.56K% |
| Profit Margin | -29.56K% |
| EBITDA Margin | -23.32K% |
| EBIT Margin | -24.53K% |
| FCF Margin | -20.41K% |
Dividends & Yields
PHAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.43% |
| FCF Yield | -39.08% |
Analyst Forecast
The average price target for PHAT is $26, which is 399% higher than the current price. The consensus rating is "Buy".
| Price Target | $26 |
| Price Target Difference | 399% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -5.24 |
| Piotroski F-Score | 3 |